Certara’s Simcyp Appoints Professor Yuichi Sugiyama to the Certara Scientific Advisory Board

June 5, 2013

The appointment will help Simcyp maintain and enhance its leadership in the field of predictive pharmacokinetic modelling and simulation.

ST. LOUIS, MO – June 5, 2013 Certara™, a leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, announced that Simcyp Limited, a Certara company and a global leader in predictive pharmacokinetics, has announced the appointment of Yuichi Sugiyama, Professor Emeritus of the Graduate School of Pharmaceutical Sciences at The University of Tokyo and Head of the Sugiyama Laboratory within the RIKEN Innovation Center to the Certara Scientific Advisory Board (SAB).

Professor Sugiyama has an outstanding academic reputation and will add value to the development of Simcyp’s market- leading platform for the prediction of drug absorption and disposition and physiologically-based pharmacokinetic-pharmacodynamic modelling as well as strengthening Simcyp’s already significant links within pharmaceutical industries.

A world-leading authority on transport mediated drug disposition and physiologically-based pharmacokinetic modelling and simulation, Professor Sugiyama has been honoured by the Japanese Government as well as by receiving numerous awards and honours from the international pharmaceutical community. Commenting on his new appointment, Professor Sugiyama stated, “I am delighted to join the Scientific Advisory Board of Certara. I believe that the work performed at Simcyp and within Certara as a whole, is both exciting and having significant impact on the evolution of model-based drug development within the pharmaceutical industry and within the world of medicines regulation.”

Simcyp develops software and databases and provides services specifically designed to inform the processes of drug discovery and development by simulating virtual patient populations, identifying individuals at extreme clinical risk and providing valuable information central to the clinical development of new medicines. Certara is dedicated to improving human health through a broad spectrum of software products and consulting services, from molecular discovery through clinical development, with special focus on supporting translational approaches to drug development.

Commenting on the appointment, Professor Malcolm Rowland, Chairman of the Certara Scientific Advisory Board, said, “We are delighted that Yuichi has agreed to join the SAB and share his internationally recognised knowledge and expertise in the area of transport mediated drug disposition and PBPK.” Dr. Daniel Weiner, Senior Vice President and General Manager of Certara said, “It is a great honour for us to have Professor Sugiyama join the Certara SAB and we look forward to him not only having impact within Simcyp but also on a wider level within Certara.”

About Certara
Certara is dedicated to improving human health through a broad spectrum of software products and consulting services, from molecular discovery through clinical development, with special focus on supporting translational approaches to drug development. Certara was formed by the acquisition and integration of industry leaders Tripos®, Simcyp™, and Pharsight® Corporation. Each Certara family brand focuses on a key phase within the drug discovery and development process; combined, they offer a unique set of scientific modeling, analysis, and simulation capabilities that can enable the cross-disciplinary approaches necessary for translational science initiatives.

Certara Contact:
Diana O’Rourke, 314-951-3310
Director of Marketing
diana.orourke@certara.com

Media Contact:
Lisa Osborne, 206-992-5245
Rana Healthcare Solutions
lisa@ranahealth.com

Learn More LinkedIn Twitter Facebook Email